There’s a vote today in New York about a full race-day Lasix ban. Some horsemen, according to a recent NYTHA survey reported by Thoroughbred Daily News, say they would run fewer horses if Lasix is prohibited. That alone tells you how entrenched this drug has become.
I’ve watched this game for over half a century. I remember when Lasix wasn’t allowed in New York — and if you wanted to be a champion, you had to run in New York. If you “needed” Lasix, you ran somewhere else. You weren’t considered first string. Fast forward to today and nearly every horse runs on it. So here’s the question nobody seems eager to ask:
If the greatest champions in history didn’t need Lasix, what happened?
The Champions Before Lasix
Before race-day furosemide became widespread in North America, the sport produced horses that were durable, consistent, and raced often.
- Secretariat — 21 starts in just over two seasons, 16 wins, raced at two and three at the highest level.
- Kelso — 63 lifetime starts over eight seasons, five consecutive Horse of the Year titles (1960–1964).
- Dr. Fager — 22 starts, 18 wins, carried massive weights, set track records.
- Native Dancer — 22 starts, 21 wins.
We can go on and on. They weren’t fragile. They weren’t managed like porcelain. They raced. They traveled. They met rivals repeatedly. They built legacies through competition — not careful spacing and pharmaceutical maintenance.
No race-day Lasix.
Then Lasix Became the Norm
Lasix (furosemide) was originally allowed to address exercise-induced pulmonary hemorrhage (EIPH), or “bleeding.” Over time, what was intended as treatment became standard operating procedure. By the 2000s, over 90% of North American starters were running on Lasix. Think about that. Are we really to believe that 90% of modern Thoroughbreds are pathological bleeders — when the legends of the past apparently weren’t? Either the breed suddenly deteriorated en masse, or something else happened: We normalized medication.
What the Science Actually Says
To be fair, studies show Lasix can reduce the severity of EIPH. That’s real. It’s documented. But Lasix is also a potent diuretic. Horses routinely lose significant fluid weight before a race. Dehydration alters physiology. Many studies show measurable performance effects tied to weight loss and fluid shifts. So when someone says, “Lasix doesn’t enhance performance,” that’s not the full picture. It absolutely changes the physiology of the animal on race day. More concerning, a 2022 peer-reviewed study found horses racing on Lasix had significantly higher odds of sudden death within three days of racing compared to those not racing on it. The absolute risk is still low — but the association exists. That cannot simply be brushed aside. If Lasix were purely a health benefit, we would expect across-the-board improvements in durability and longevity. We haven’t seen that.
Field Sizes and Durability Tell the Story
In the 1970s, horses averaged 10 or more starts per year. Today, many elite horses make 5 or 6. Field sizes nationally have trended downward over the past four decades. Fewer horses per race. Fewer starts per horse. Shorter careers. Lasix became ubiquitous during that same period.
Has it reversed decline? No. Has it made horses more durable? The data doesn’t show that. Has it strengthened the breed? That’s hard to argue when careers are shorter than ever. The pro-Lasix argument is often framed as welfare. But if nearly every horse is medicated and the sport is still shrinking — smaller fields, shorter careers — then something isn’t adding up.
The Rest of the World Doesn’t Allow It
Major racing jurisdictions — the UK, Ireland, France, Japan, Australia — prohibit race-day Lasix. They still produce champions. They still fill fields. They still build rivalries. They still beat us. If Lasix were indispensable for horse welfare, the rest of the world would be using it on race day. They’re not. North America stands largely alone.
So What Happened?
Here’s what happened in my view:
We started treating the exception as the rule. Instead of identifying true bleeders, we medicated the population. Instead of breeding for durability, we bred for speed and managed fragility. We bred to sell, not to race. Instead of asking whether universal medication was masking a deeper problem, we accepted it as the cost of doing business. And somewhere along the way, we convinced ourselves that nearly every horse “needs” it. The champions didn’t. Were they freaks? Or were they products of a system that demanded soundness and stamina?
The Vote Isn’t Just About Lasix
The current debate in New York isn’t just regulatory housekeeping. It’s philosophical. Some horsemen say they’ll race less without Lasix. That’s telling. It means the business model has adapted to medication dependency. But if all those champions ran without it — and thrived — why are we so certain today’s horses can’t? If 90% of horses are “bleeders,” maybe the question isn’t whether Lasix works. Maybe the question is what we’ve bred, trained, and normalized.
Final Thought
Lasix may reduce the severity of bleeding in some horses. That’s fair.
But it has not:
- Restored durability.
- Increased field sizes.
- Lengthened careers.
- Reversed the sport’s decline.
And when almost every starter runs on it, you can’t call it treatment anymore. It’s policy. The great ones — Secretariat, Kelso, Dr. Fager, Native Dancer — didn’t need a race-day IV to prove they belonged.
Maybe the real question isn’t whether Lasix should be banned. Maybe it’s this:
Are we willing to breed and race horses that don’t need it?
